Non-Invasive Brain Stimulation Technologies for the Treatment of Alzheimer’s, Dementia & Parkinson’s
Updated: Sep 21
Neurodegenerative diseases are disorders characterized by the progressive deterioration of the nervous system’s structure and function, leading to the person’s functional decline. These diseases affect millions of people around the world, being the most common Alzheimer’s and Parkinson’s disease.
Alzheimer’s disease is a disorder that gradually evolves into dementia. Its main symptoms are memory loss, language deterioration, problems to manipulate visual information, poor judgment, confusion, restlessness, and mood swings. These changes occur progressively, producing eventual destruction of cognition, personality, and the ability to function independently even in daily life tasks.
Nowadays, Alzheimer’s disease affects nearly 5 million people in the USA and 50 million worldwide. Currently, no medication, intervention, surgery or device can stop nor slow disease progression. Actipulse Neuroscience is a medical startup that aims to change this situation. The main hypothesis of Actipulse is that there are no effective treatments for Alzheimer’s because the last 30 years of research have focused on targeting one single mechanism of the disease: Beta-Amyloid deposition. They have developed a novel non-invasive brain stimulation device that targets not just one mechanism of the disease but several of those. By targeting multiple pathways of the disease, they hope to stop the cascade that ultimately is leading to neurodegeneration. Also, this device can be applied directly and safely from home without the close supervision of a health professional, which would become extremely useful to patients as they will not need to go each day to a clinical site to receive their daily dose of brain stimulation.
Actipulse Neuroscience is currently running a double-blinded sham-controlled pilot clinical trial with 80 patients with Alzheimer’s disease in which they are aiming to prove that this device could reduce cognitive symptoms in patients suffering from this debilitating disease. Preliminary blinded data from their trial has shown some promising results in bringing solutions for Alzheimer’s disease by improving cognition in some patients.
Last but not least, Actipulse is planning to launch several pilot clinical trials using its proprietary device to address other neurodegenerative and neurological disorders in this same year.
Gabriel Vllafuerte's book recommendation: I Am a Strange Loop, by Douglas R. Hofstadter: